Cytovance Biologics to expand microbial manufacturing
Has acquired 100L and 1,000L fermenters
Cytovance Biologics, a contract manufacturer of mammalian and microbial biologics, is to expand its microbial manufacturing capabilities. In addition to its current 100L fermenter, the firm recently acquired a second 100L and a 1000L fermenter.
Applicable processing and downstream equipment upgrades to support this larger scale will also be acquired.
Cytovance is currently planning a facility expansion to house these new systems.
‘This increase in microbial manufacturing capacity is to meet growing customer demands for microbial fermentation services,’ said Darren Head, President and CEO of Cytovance.
‘This marks another milestone in our contract manufacturing strategy of providing clinical material to key clients as they move though the clinic and into commercial manufacturing.’
This increase in microbial manufacturing capacity is to meet growing customer demands for microbial fermentation services
In January, Cytovance said it would expand its mammalian manufacturing capabilities with the inclusion of a 5000L stainless steel bioreactor. This will compliment existing manufacturing process trains that include 100L, 500L and 1,000L bioreactors, 100L wave system and 50L and 200L Sartorius subs.
Cytovance continues to provide analytical method development and process development for Phase I, II, and III clinical trial materials as well as regulatory expertise to support validation and commercial market launch for therapeutic proteins, recombinant proteins and monoclonal antibodies.
Cytovance Biologics specialises in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its facilities in Oklahoma City.
